Bailard, Inc. Neogenomics Inc Transaction History

Bailard, Inc.

$3.8 Billion
Q1 2025

A detailed history of Bailard, Inc. transactions in Neogenomics Inc stock. As of the latest transaction made, Bailard, Inc. holds 19,300 shares of NEO stock, worth $143,206. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,300

Holding current value

$143,206

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 02, 2025	BUY	$9.09 - $18.61 $175,437 - $359,173	19,300 New	19,300 $183,000
Q1 2024 May 08, 2024	BUY	$14.06 - $16.79 $188,404 - $224,986	13,400 New	13,400 $210,000

Others Institutions Holding NEO

# of Institutions

288

Shares Held

127M

Call Options Held

942K

Put Options Held

172K

Black Rock Inc. New York, NY

19.7M
Shares

$146 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

14.3M
Shares

$106 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

6.72M
Shares

$49.8 Million
0.04% of portfolio
First Light Asset Management, LLC Edina, MN

6.04M
Shares

$44.8 Million
7.36% of portfolio
Janus Henderson Group PLC London, X0

5.74M
Shares

$42.6 Million
0.03% of portfolio

View Full List

About NEOGENOMICS INC

Ticker NEO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 125,796,000
Market Cap $933M
Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...

More about NEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account